Prostate Cancer | Specialty

Cardio-Oncology and Prostate Cancer

March 25th 2019

NCCN Guidelines Update Increases Role of Genetic Testing in Prostate Cancer

March 23rd 2019

Emmanuel S. Antonarakis, MD, discusses the prevalence of mismatch repair and homologous recombination deficiency genes and how they may play a role in determining a patient’s treatment plan in addition to promising agents that have been introduced to the field in clinical trials.

Dr. Slovin Discusses History of Immunotherapy in Prostate Cancer

March 22nd 2019

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the history of immunotherapy in the treatment of patients with prostate cancer.

Dr. Gomella Discusses Role of BRCA1/2 in Prostate Cancer

March 22nd 2019

Leonard Gomella, MD, professor, chair, Department of Urology, director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the role of BRCA1/2 in patients with prostate cancer.

CTC AR-V7 Validated as Predictive Marker of Resistance to AR-Directed Therapy in mCRPC

March 14th 2019

AR-V7 protein in circulating tumor cells is a predictive marker of shorter progression-free and overall survival with antiandrogen therapy in patients with metastatic castration-resistant prostate cancer.

Dr. Scholz on Significance of ARAMIS Trial in CRPC

March 13th 2019

Mark Scholz, MD, medical director, Prostate Oncology Specialists, discusses the significance of the ARAMIS trial in the treatment of patients with metastatic castration-resistant prostate cancer.

Posadas Breaks Down Rapidly Evolving Prostate Cancer Paradigm

March 8th 2019

Edwin M. Posadas, MD, FACP, discusses recent prostate cancer data and sheds light on where emerging therapies may fit into this landscape.

Dr. Dorff on PARP Inhibitors in Prostate Cancer

March 7th 2019

Tanya B. Dorff, MD, associate clinical professor in the Department of Medical Oncology and Therapeutics Research, and head of the genitourinary cancers program at City of Hope, discusses the use of PARP inhibitors in prostate cancer.

BCL-2 Emerges as an Attractive Target in Solid and Hematologic Cancers

March 6th 2019

Based on the crucial role of BCL-2 family proteins in apoptosis regulation, targeting these proteins using BCL-2 inhibitors offers a potentially new therapeutic option for patients with various types of hematologic malignancies and, more recently, patients with solid tumors.

Japanese Approval Sought for Darolutamide in CRPC

March 6th 2019

An application has been submitted to Japan's Ministry of Health, Labor and Welfare for darolutamide for the treatment of patients with castration-resistant prostate cancer.

Personalized Medicine Is Next Step in Castration-Resistant Prostate Cancer

March 4th 2019

Raoul S. Concepcion, MD, FACS, discusses the clinical implications of the findings from the ARAMIS trial and highlights other therapies that are coming down the pike for the treatment of patients with castration-resistant prostate cancer.

Dr. Fleming Discusses Importance of QoL in Prostate Cancer

March 2nd 2019

Mark T. Fleming, MD, medical oncologist, Virginia Oncology Associates, associate chair, Genitourinary Research Committee, US Oncology Network, discusses the focus on quality of life in recent prostate cancer clinical trials.

Dr. Armstrong Discusses ARCHES Trial in Prostate Cancer

March 1st 2019

Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the ARCHES trial in patients with metastatic hormone-sensitive prostate cancer.

Pre-existing Cardiovascular Disease Linked to Higher Mortality With Abiraterone

February 28th 2019

Pre-existing cardiovascular disease was associated with an increased mortality risk during the first 6 months of abiraterone acetate treatment in patients with advanced prostate cancer.

FDA Approval Sought for Darolutamide for Nonmetastatic CRPC

February 27th 2019

A new drug application has been filed with the FDA for darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer. ​

Dr. Concepcion on Potential for Immunotherapy in CRPC

February 27th 2019

Raoul S. Concepcion, MD, FACP, director, Comprehensive Prostate Center, discusses the potential for immunotherapy in the treatment of patients with castration-resistant prostate cancer.

Dr. Slovin Discusses Risk Factors for ADT-Associated Cardiac Complications in Prostate Cancer

February 26th 2019

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses risk factors for androgen deprivation therapy (ADT)-associated cardiac complications in prostate cancer.

Dr. Yu Discusses Treatment Strategies for Patients With Oligometastatic Prostate Cancer

February 23rd 2019

Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses treatment strategies for patients with oligometastatic prostate cancer.

Expert Highlights Nivolumab/Ipilimumab Potential in mCRPC

February 23rd 2019

Sumit K. Subudhi, MD, PhD, discusses the promise of the combination of nivolumab and ipilimumab in patients with metastatic castration-resistant prostate cancer and the challenges that lie ahead with this treatment approach.

SM-88 Safe, Active in Nonmetastatic CRPC

February 22nd 2019

Benjamin A. Gartrell, MD, discusses the promise of SM-88 in this patient population, as well as other therapeutic options that are emerging for various prostate cancer subtypes.